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Myocardial perfusion scintigraphy in the detection of silent
ischemia in asymptomatic diabetic patients*
Cintilografia de perfusão miocárdica na detecção da isquemia silenciosa em pacientes diabéticos
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Objective: This study was aimed to evaluate myocardial perfusion in asymptomatic patients with type 1 (DM1) and
type 2 diabetes mellitus (DM2) without previous diagnoses of coronary artery disease (CAD) or cerebral infarction.
Materials and Methods: Fifty-nine consecutive asymptomatic patients (16 DM1, 43 DM2) underwent myocardial
perfusion scintigraphy with 99mTc-sestamibi (MPS). They were evaluated for body mass index, metabolic control of DM,
type of therapy, systemic arterial hypertension, dyslipidemia, nephropathy, retinopathy, peripheral neuropathy, smoking,
and familial history of CAD. Results: MPS was abnormal in 15 patients (25.4%): 12 (20.3%) with perfusion abnormalities,
and 3 with isolated left ventricular dysfunction. The strongest predictors for abnormal myocardial perfusion were: age
60 years and above (p = 0.017; odds ratio [OR] = 6.0), peripheral neuropathy (p = 0.028; OR = 6.1), nephropathy
(p = 0.031; OR = 5.6), and stress ECG positive for ischemia (p = 0.049; OR = 4.08). Conclusion: Silent myocardial
ischemia occurs in more than one in five asymptomatic diabetic patients. The strongest predictors of ischemia in this
study were: patient age, peripheral neuropathy, nephropathy, retinopathy and a stress ECG positive for ischemia.
Keywords: Diabetes mellitus; Myocardial perfusion imaging; Silent myocardial ischemia; Coronary artery disease.
Objetivo: Este estudo teve por finalidade avaliar a perfusão miocárdica de pacientes com diabetes mellitus tipo 1
(DM1) e tipo 2 (DM2) assintomáticos, sem diagnóstico prévio de doença arterial coronariana (DAC) ou acidente vas-
cular cerebral. Materiais e Métodos: Cinquenta e nove pacientes consecutivos (16 DM1, 43 DM2) foram submeti-
dos a cintilografia de perfusão miocárdica com sestamibi-99mTc (CPM). Foram avaliados quanto ao índice de massa
corpórea, controle metabólico do diabetes, dislipidemia, terapia para o diabetes, hipertensão arterial sistêmica, nefro-
patia, retinopatia, neuropatia periférica, tabagismo e história familiar de DAC. Resultados: CPM foi anormal em 25,4%:
12 (20,3%) com alterações de perfusão e 3 com disfunção ventricular esquerda isolada. Os mais fortes preditores de
perfusão miocárdica anormal foram: idade igual ou maior a 60 anos (p = 0,017, odds ratio [OR] = 6,0), neuropatia
periférica (p = 0,028, OR = 6,1), nefropatia (p = 0,031, OR = 5,6) e ECG de esforço positivo para isquemia (p =
0,049, OR = 4,08). Conclusão: A isquemia miocárdica silenciosa ocorre em mais de um em cada cinco diabéticos
assintomáticos. Os mais fortes preditores de isquemia foram: idade avançada, neuropatia periférica, nefropatia, reti-
nopatia e ECG de esforço positivo para isquemia.
Unitermos: Diabetes mellitus; Cintilografia de perfusão miocárdica; Isquemia miocárdica silenciosa; Doença arterial
coronariana.
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INTRODUCTION
Coronary artery disease (CAD) is the
leading cause of mortality in diabetic pa-
tients. In these individuals, CAD is usually
more advanced at the time of diagnosis and
frequently presents an unfavorable progno-
sis. In addition, patients with diabetes have
a high incidence of occult CAD, observed
as an increased occurrence of silent myo-
cardial infarction (SMI) and not typically
associated with angina, probably because
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of diabetic autonomic neuropathy(1,2).
These factors have raised the interest in
investigating CAD before its first clinical
expression in diabetic patients and non-
invasive tests have been advocated as an
essential tool for early detection of the dis-
ease(3).
In general, individuals with diabetes
have at least a twofold to fourfold increased
risk for cardiovascular events when com-
pared with age-matched subjects without
diabetes. It is estimated that SMI preva-
lence in this group ranges from 10% to
20% versus from 1% to 4% estimated for
non diabetic populations(4). After myocar-
dial infarction, diabetic patients have a
twofold to threefold greater morbidity and
mortality. The high risk of CAD in these
patients took the American Heart Associa-
tion to not only determine diabetes as a
major independent risk factor for the devel-
opment of CAD as to establish that diabe-
tes is a cardiovascular disease(5).
Asymptomatic diabetic patients with in-
creased risk for CAD can benefit of myo-
cardial perfusion scintigraphy with 99mTc-
sestamibi (MPS) because this scintigraphic
test cost-effectively measures and stratifies
risk. Therefore this test is a good alterna-
tive to cineangiocoronariography or tread-
mill test(6). Even so, many authors have
been using cineangiocoronariography as
gold standard for CAD(3,7). However, those
studies do not take into account the mi-
crovascular pathophysiology of diabetes
mellitus for which cineangiocoronariogra-
phy and stress electrocardiogram (ECG)
have a lower sensitivity(5). Indeed, there is
consistent evidence that diabetes causes al-
terations in the regulation of coronary va-
sodilator function in both epicardial and re-
sistance coronary vessels, which are
present before the appearance of obstruc-
tive CAD(8). Thus, functional imaging can
more accurately identify endothelial cell
dysfunction within coronary microvascu-
lature among diabetic patients.
Considering that MPS is relatively ex-
pensive to be used as a screening test, it is
necessary to select subgroups of diabetic
patients who present an increased risk for
CAD, and that will effectively benefit of
systematic screening for myocardial perfu-
sion abnormalities. This study was aimed
to evaluate myocardial perfusion in dia-
betic patients type 1 (DM1) and type 2
(DM2) without previous diagnoses or
symptoms of CAD and cerebral infarction,
as well as to evaluate clinical and labora-
tory predictors of abnormal test results.
MATERIALS AND METHODS
The study was approved by the ethics
committee of the institution and all patients
signed a written consent form. The authors
do not have any conflict of interest in this
project.
During a 12-month period, consecutive
patients who met the inclusion criteria were
invited by endocrinologists during their
clinical appointments to participate in the
protocol. Fifty-nine patients with the diag-
nosis of DM (16 type 1 and 43 type 2) were
prospectively studied (44 women and 15
men; ages 26 to 74 years; mean 49.4 ± 12.2
years). Disease duration was 14.3 ± 7.2
years. Inclusion criteria were: diagnosis of
type 1 diabetes or type 2 diabetes (accord-
ing to American Diabetes Association cri-
teria)(9); age between 18 and 75 years. Ex-
clusion criteria were: presence of clinical
symptoms or ECG signs of CAD, history
of cerebral infarction or myocardial infarc-
tion, coronary revascularization or heart
failure, and pregnancy.
Patients were clinically evaluated by the
endocrinologist and the nuclear medicine
physician about sex, age, type of diabetes,
disease duration, treatment (insulin, insu-
lin plus oral agents or oral agents), meta-
bolic control of diabetes, systemic arterial
hypertension (≥ 140 mmHg systolic blood
pressure and/or ≥ 90 mmHg diastolic blood
pressure) or treatment with an antihyperten-
sive drug, smoking, body mass index
(BMI) (kg/m2), regular physical activity,
familial history of CAD, dyslipidemia or
hypolipemic treatment, and presence of
diabetic nephropathy, retinopathy, and pe-
ripheral neuropathy. The laboratory evalu-
ation included: hemoglobin A1c level
(good control HbA1c < 7%), total serum
cholesterol (normal value: < 200 mg/dl),
LDL cholesterol (normal value: < 100 mg/
dl), HDL cholesterol (normal value: > 40
mg/dl for males and > 50 mg/dl for fe-
males), triglycerides (normal value: < 150
mg/dl), albumin to creatinine ratio, as the
mean of 3 nonconsecutive morning spot
urine samples (microalbuminuria: ≥ 30 to
299 mg/g creatinine, and macroalbuminuria:
≥ 300 mg/g creatinine)(10). Fundoscopy re-
ports by an eye-care professional were
evaluated for the presence and stage of dia-
betic retinopathy. Patients were tested for
peripheral neuropathy (sensation to touch
by monofilament and vibration sensation
by tuning fork and Achilles tendon reflex
by reflex hammer). Clinical findings are
summarized in Table 1.
Stress SPECT myocardial perfusion
imaging
All patients underwent MPS. Patients
were oriented to suspend xanthines and
nitrates one day before, beta-blockers three
days before, and calcium channel blockers
five days before the scintigraphy. Rest and
stress imaging were performed on the same
day. First it was acquired resting tomo-
graphic images (SPECT) after the injection
of 10 mCi (370 MBq) of sestamibi-99mTc
with the following parameters: high-reso-
lution collimator, matrix 64 × 64, angle
range 186°, angle step 6°. Patients were
then submitted to stress by the cardiologist
(exercise or pharmacological stress with
dipyridamole) and received an injection of
30 mCi (1110 MBq) at stress peak. Later
acquisition of stress imaging followed the
same gamma-camera parameters but it was
also synchronized to the ECG (GATED
SPECT). The left ventricle ejection fraction
(LVEF) derived from these ECG-gated
images. In the course of scintigraphy, elec-
trocardiograms were recorded, at rest and
after stress, and analyzed by the cardiolo-
gist. All patients who presented perfusion
defects in the inferior wall at the stress
imaging repeated the acquisition in prone
position to evaluate diaphragmatic arti-
facts. Scintigraphies were visually ana-
lyzed by two nuclear medicine physicians
and, if abnormal, quantified with the 17-
segment method(11).
When necessary, semiquantitative 17-
segment visual interpretation was per-
formed using a 5-point scoring system (0,
normal; 1, mild; 2, moderate; 3, severe re-
duction of radioisotope uptake; and 4, ab-
sence of detectable tracer uptake). The
summed stress score and summed rest
score were obtained by adding the scores
of the 17 segments of the respective im-
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ages. The sum of the differences between
each of the 17 segments from these images
was defined as the summed difference
score, representing the amount of ischemia.
Each of these variables incorporates the
extent and severity of perfusion defects,
which independently add prognostic infor-
mation. These indices were converted to
percent of the total myocardium involved
with stress, ischemic, or fixed defects by di-
viding the summed scores by 68, the maxi-
mum potential score in the 17-segment
model (4 × 17), and multiplying by 100(11).
Statistical analyses
Statistical analyses were performed
with SAS software (SAS Institute Inc.;
Cary, NC, USA). First, data from both
groups (DM1 and DM2) were statistically
analyzed together, using descriptive statis-
tics (mean, standard deviation, minimum,
median, and maximum) for continuous
variables, and tables of frequencies for cat-
egorical variables. Chi-square test and
Fisher’s exact test were used to compare the
categorical variables between the two
groups (normal MPS and abnormal MPS)
and Mann-Whitney test was used to com-
pare the numerical variables due to the lack
of normal distribution of the variables. To
determine independent risk factors related
with ischemia and/or fixed defect a logis-
tic regression analysis was performed, us-
ing univariate and multiple models, with
stepwise criterion for variable selection. A
p value < 0.05 was considered significant.
After this first evaluation, data from the
DM2 group was analyzed separately, also
using the descriptive statistics and the same
tests.
The age cutoff according to the presence
of abnormalities in MPS, in order to maxi-
mize sensitivity and specificity, was deter-
mined by receiver operating characteristic
(ROC) curve analysis.
RESULTS
MPS was abnormal in 15/59 patients
(25.4%): 12 with perfusion defects (2/16
DM1 and 10/43 DM2) and 3 with left ven-
tricular dysfunction, defined by ejection
fraction under 45% (3/43 DM2). For sta-
tistical analyses, it was considered as ab-
normal only the group with perfusion de-
fects (n = 12), since isolated left ventricu-
lar dysfunction could represent diabetic or
hypertensive cardiomyopathy instead of
true silent ischemia. Therefore in our study
the term “silent ischemia” would best de-
scribe patients with myocardial perfusion
abnormalities.
Among patients with abnormal perfu-
sion tests (n = 12), we had 2 with fixed
defects and 10 with ischemia. Considering
the 17-segment quantification(11) and estab-
lishing a cut off of 10%, we had 7 low risk
cases (quantification < 10%), and 5 high
risk cases (quantification ≥ 10%) including
1 patient with TID (transient ischemic di-
lation) which was also considered high risk
even though it was not possible to quantify
it by the same method. Still considering
these subgroup, we had 3 patients with left
ventricular dysfunction (LVEF < 45%) as-
sociated to the perfusion defect (Table 2).
In this subgroup we also observed 5 pa-
tients with ischemic stress tests (1 exercise
and 4 dipyridamole), and 7 patients with
normal stress tests (3 exercise and 4 dipy-
ridamole). On the other hand in the normal
MPS group, 41 patients had normal stress
tests (28 exercise and 13 dipyridamole),
and 6 patients had ischemic stress tests (4
exercise and 2 dipyridamole).
The ROC curve analysis for age, using
the presence of silent ischemia as the gold
standard, revealed the age of 60 years as the
cutoff that maximizes sensitivity and speci-
ficity. Similarly, comparative analysis of
age (continuous variable) between groups
with and without silent ischemia in the to-
tal sample showed a median of 58.0 years
for the group of patients with perfusion
abnormalities (p = 0.026, Mann Whitney’s
test).
The prevalence of positive screening
tests to silent ischemia varied according to
type of diabetes. In the type 1 diabetes group,
2 of 16 patients (12.5%) had abnormal per-
fusion tests (both women, 35 and 46 years
old, and duration of diabetes of 17 and 18
years respectively). The stress ECG was
normal in these 2 patients. Retinopathy,
nephropathy and peripheral neuropathy
were present in the first patient and were
absent in the other patient. In the type 2
diabetes group, 10 of 43 patients (23.25%),
including 4 men and 6 women, had posi-
tive tests (2 fixed defect and 8 ischemic).
The ages of patients had ranged between 46
to 74 years and the maximum time of dura-
tion of disease was 28 years. The stress ECG
was abnormal in half of these 10 patients.
Unlikely the DM1 group, retinopathy and
nephropathy were present in 80% (8/10)
and neuropathy was present in 90% (9/10)
Table 1 Clinical characteristics of the 59 patients.
Characteristics
n
Sex (male / female)
Age (years)
Body mass index (kg/m2)
Duration of diabetes (years)
Treatment
– Oral agent (%)
– Insulin plus oral agent (%)
– Insulin (%)
HbA1c (%)
Retinopathy (%)
Nephropathy (%)
– Microalbuminuria
– Macroalbuminuria
Neuropathy (%)
Smokers (%)
Dyslipidemia (%)
Hypertension (%)
Family history of CAD
Type 2 diabetes
43
10 male / 33 female
54.7 ± 8.9 (34 to 74)
30.9 ± 6.3
13.6 ± 7.7
34.8 (15/43)
51.2 (22/43)
14.0 (6/43)
8.8 ± 1.8
48.8 (21/43)
23.2 (10/43)
27.9 (12/43)
55.8 (24/43)
20.9 (9/43)
79.0 (34/43)
90.6 (39/43)
41.8 (18/43)
Type 1 diabetes
16
5 male / 11 female
35.1 ± 7.6 (26 to 50)
27.0 ± 5.2
16.3 ± 5.9
0 (0/16)
12.5 (2/16)
87.5 (14/16)
9.1 ± 1.9
50 (8/16)
12.5 (2/16)
25 (4/16)
43.7 (7/16)
18.7 (3/16)
62.5 (10/16)
62.5 (10/16)
25 (4/16)
Data are means ± standard deviation or % of affected patients. CAD, coronary arterial disease.
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of DM2 patients with perfusion abnormali-
ties. However, these different rates of preva-
lence between the diabetic groups (type 1
and type 2) could not be statistically ana-
lyzed due to the reduced number of DM1
patients included in the study (Table 2).
Considering the 12 patients with abnor-
mal MPS (2 DM1 and 10 DM2), statisti-
cal analyses of categorical variables using
Chi-square test and Fisher’s exact test re-
vealed to be statistically significant predic-
tors of the presence of silent ischemia in
diabetics patients: age 60 years and above
(p = 0.022), retinopathy (p = 0.045), neph-
ropathy (p = 0.032), and peripheral neur-
opathy (p = 0.017) (Table 3).
Conversely, no difference was observed
between the two groups, with and without
ischemia, regarding gender, BMI, duration
of diabetes, type of treatment, HbA1c level,
dyslipidemia, arterial hypertension, smok-
ing, abnormal stress ECG, physical activ-
ity or familial history of DAC.
Univariate logistic regression analysis
showed to be statistically significant pre-
dictors of silent ischemia: age 60 years and
above (p = 0.017; odds ratio [OR] = 6.0),
abnormal stress ECG (p = 0.049; OR =
4.08), nephropathy (p = 0.042); OR =
4.42), and peripheral neuropathy (p =
0.028; OR = 6.19). Additionally, a signifi-
cant correlation was observed between si-
lent ischemia and macroalbuminuric neph-
ropathy (p = 0.031; OR = 5.60) (Table 4).
Multiple logistic regression analysis
showed that the variables which better in-
Table 2 Characteristics of 12 patients with perfusion defects.
Patient
1
2
3
4
5
6
7
8
9
10
11
12
Sex
Female
Female
Female
Female
Male
Female
Male
Female
Male
Female
Female
Male
Age
(years)
46
35
58
46
74
61
46
55
66
68
58
72
Type
of DM
1
1
2
2
2
2
2
2
2
2
2
2
Nephropathy
Macroalbuminuria
No
No
Macroalbuminuria
Microalbuminuria
Microalbuminuria
Macroalbuminuria
Microalbuminuria
Macroalbuminuria
Macroalbuminuria
No
Macroalbuminuria
Retinopathy
Yes
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Neuropathy
Yes
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
Stress
ECG
Normal
Normal
Normal
Abnormal
Abnormal
Abnormal
Abnormal
Normal
Normal
Normal
Normal
Abnormal
LVEF
(%)
52
56
69
43
52
56
39
55
52
47
> 70
33
MPS
Ischemia
Ischemia
Ischemia
Ischemia
Ischemia
Ischemia
Fixed defect
Ischemia
Ischemia
Fixed defect
TID
Ischemia
Quantification*
(%)
7
6
6
6
7
37
12
12
6
12
—
9
DM, diabetes mellitus; LVEF, left ventricular ejection fraction; MPS, myocardial perfusion scintigraphy; TID, transient ischemic dilation.
* Quantification with the 17-segment method(12).
Table 3 Clinical characteristics of patients with or without silent coronary disease.
Characteristics
n
Sex (male/female)
Age (< 60 / ≥ 60 years)
Type of DM (1/2)
Body mass index (< 25 / ≥ 25 kg/m2)
Duration of disease (< 15 / ≥ 15 years)
Use of insulin (Yes/No)
HbA1c (< 7 / ≥ 7%)
Retinopathy (Yes/No)
Nephropathy (Yes/No)
– Microalbuminuria
– Macroalbuminuria
Neuropathy (Yes/No)
Smokers (Yes/No)
Hypertension (Yes/No)
Dyslipidemia (Yes/No)
Familial history of CAD (Yes/No)
Regular physical activity (Yes/No)
Stress ECG positive for ischemia (Yes/No)
Abnormal
perfusion
12
4/8
7/5
2/10
1/11
5/7
9/3
3/9
9/3
9/3
3/9
6/9
10/2
4/8
12/0
9/3
4/8
3/9
5/7
p value
NS
0.022*
NS
NS
NS
NS
NS
0.045†
0.032†
NS
NS
0.017†
NS
NS
NS
NS
NS
NS
Normal
perfusion
47
11/36
42/5
14/33
10/37
26/21
35/12
7/40
20/27
19/28
9/19
10/19
21/26
8/39
37/10
35/12
18/29
8/39
7/40
NS, non significant; DM, diabetes mellitus; CAD, coronary arterial disease.
* Fisher’s exact test (p value < 0.05); † Chi-square test (p value < 0.05).
Table 4 Univariate logistic regression analysis for ischemia (p value < 0.05).
Age (< 60 / ≥ 60 years)
Stress ECG positive for
ischemia (Yes/No)
Nephropathy (Yes/No)
– Microalbuminuria
– Macroalbuminuria
Neuropathy (Yes/No)
MPS
abnormal
n = 12
7/5
5/7
9/3
3/9
6/9
10/2
MPS
normal
n = 47
42/5
7/40
19/28
9/19
10/19
21/26
p value
0.017
0.049
0.042
NS
0.031
0.028
OR
6.0
4.08
4.42
3.11
5.60
6.19
CI 95% OR
1.37–26.24
1.01–16.56
1.06–18.48
0.53–18.22
1.17–26.72
1.22–31.39
MPS, myocardial perfusion scintigraphy; OR, odds ratio; CI, confidence interval; NS, non significant.
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dicates concomitant silent ischemia in dia-
betic patients are: age 60 years and above
(p = 0.039; OR = 5.21), and peripheral neu-
ropathy (p = 0.045; OR = 5.54) (Table 5).
As the small number of patients with
DM1 included in the study did not allow
an individual statistical analysis of this sub-
group, we conducted a separate analysis
only the subset of patients with DM2.
The ROC curve analysis for age in DM2
patients, using the presence of silent is-
chemia as the gold standard, revealed the
same cutoff of 60 years. Similarly, com-
parative analysis of age (continuous vari-
able) between groups with and without si-
lent ischemia showed a median of 59.5
years for the group of DM2 patients with
perfusion abnormalities (p = 0.041; Mann
Whitney’s test).
Still considering only the 10 DM2 pa-
tients with abnormal scintigraphy, the sta-
tistical analysis of categorical variables
using Fisher’s exact test revealed to be sta-
tistically significant predictors of the pres-
ence of silent ischemia in DM2: age 60
years and above (p = 0.036), diabetic ret-
inopathy (p = 0.034), and peripheral neur-
opathy (p = 0.026). Unlike the statistical
analysis of the total sample, which assessed
the DM1 and DM2 together, the presence
of diabetic nephropathy was not statisti-
cally significant when DM2 patients were
analyzed separately.
The univariate logistic regression analy-
sis showed as statistically significant pre-
dictors of silent ischemia in DM2 patients:
age 60 years and above (p = 0.031; OR =
5.6), diabetic retinopathy (p = 0.036; OR
= 6.15), peripheral neuropathy (p = 0.032;
OR = 10.8), and macroalbuminuric nephr-
opathy (p = 0.043; OR = 6.79) (Table 6).
Finally, multiple logistic regression
analysis showed that the variable which
best indicates possible silent ischemia in
DM2 subjects is the presence of peripheral
neuropathy (p = 0.032; OR = 10.8).
DISCUSSION
Diabetes is associated with a twofold to
fourfold risk increase of developing CAD
compared with age-matched subjects with-
out diabetes(12–14). Many studies have been
designed to evaluate the presence of silent
myocardial ischemia in asymptomatic dia-
Figure 2. Clinical case 2. A 68-year-old woman with diabetes type 2 for 16 years and clinical manifes-
tations of diabetic nephropathy, retinopathy, and peripheral neuropathy. Patient was asymptomatic. Phar-
macological stress with dipyridamole was negative for ischemia. MPS showed fixed defect with ischemic
component; 17-segment quantification = 12%.
Figure 1. Clinical case 1. A 61-year-old woman with diabetes type 2 for 28 years and clinical manifes-
tations of diabetic nephropathy, retinopathy, and peripheral neuropathy. Patient was asymptomatic. Phar-
macological stress with dipyridamole was positive for ischemia. MPS showed ischemia; 17-segment quan-
tification = 37%.
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betic patients and their prevalence rates
range from 9% to 57%(2,7,15–24). The reason
for this broad range is probably due to dif-
ferences in the populations studied, includ-
ing age of patients, duration of disease,
inclusion and exclusion criteria and defi-
nition and diagnosis of SMI. Two relatively
recent large retrospective studies from Ce-
dars Sinai (n = 826)(25) and the Mayo Clinic
(n = 1427)(26) reported abnormal stress
SPECT images in 39% and 58% of asymp-
tomatic diabetic patients, respectively.
However, retrospective studies have sev-
eral limitations, including selection bias of
higher-risk patients.
The most important prospective study
using stress SPECT imaging, the Detection
of Ischemia in Asymptomatic Diabetics
(DIAD) study(2), evaluated 1123 patients
with type 2 diabetes, aged 50–75 years,
with no known or suspected CAD. Those
patients were randomly assigned to either
stress testing and 5-year clinical follow-up
or to follow-up only (no imaging). A total
of 113 patients (22%) had evidence of si-
lent myocardial ischemia, including 83
with regional myocardial perfusion abnor-
malities and 30 with normal perfusion but
other abnormalities (i.e., adenosine-in-
duced ST-segment depression, ventricular
dilation, or rest ventricular dysfunction).
Moderate or large perfusion defects were
present in 33 patients. The strongest predic-
tors for abnormal tests were abnormal Val-
salva, male sex, and diabetes duration.
Other traditional cardiac risk factors or in-
flammatory and prothrombotic markers
were not predictive. The findings of the
first phase of DIAD study suggest that
greater than one in five asymptomatic pa-
tients with type 2 diabetes, aged 50–75
years, have silent ischemia. Considering
that the DIAD patient population was truly
representative of asymptomatic patients
with type 2 diabetes without any clinical
reason to suspect CAD, the prevalence of
SMI indicates that totally asymptomatic
diabetic patients have at least an interme-
diate probability of CAD, justifying screen-
ing by noninvasive testing such as stress
myocardial perfusion imaging(2).
In our study, the prevalence of SMI was
20.3%, which is similar to DIAD results
and to several other studies of the litera-
ture(2,7,21). Although the prevalence of SMI
was different when we compared the DM1
and DM2 groups (12.5% versus 23.25%,
respectively), this difference was not sta-
tistically significant, probably due to the
small number of type 1 diabetics studied.
The association between autonomic
neuropathy and asymptomatic ischemia has
been demonstrated by several prior stud-
ies(27–29). Similarly, we did not find signifi-
cantly association among duration of dis-
ease, type of diabetes and treatment, BMI,
smoking, physical activity, familial history
of DAC, dyslipidemia, arterial hyperten-
sion, abnormal stress ECG, HbA1c level and
presence of silent ischemia. The univariate
and multiple logistic regression analyses
revealed that age 60 years and above, but
no male sex, was a strong predictive risk
factor for myocardial ischemia. Both analy-
ses also showed that peripheral neuropathy
in our diabetic patients was significantly
correlated to silent ischemia. Although we
did not have conducted any tests for detec-
tion of autonomic neuropathy, we can con-
sider peripheral neuropathy as a predictor
of ischemia, since it is present in most pa-
tients with diabetic dysautonomia.
However we had a predominance of fe-
male patients, although there are no pub-
lished data that suggest a higher prevalence
of diabetes in this sex. We believe that the
larger number of women in our study is
related to the greater availability of them to
participate in research protocols. A similar
number of men and women were invited to
participate in the protocol, however, more
women accepted the invitation and at-
tended the laboratory on the day of the test.
Many male patients who initially agreed to
participate, did not attend the appointment.
The progress made in detection and
treatment of CAD allows reconsidering the
screening of silent ischemia, in the hope
that early CAD diagnosis leads to a more
effective therapy and the decrease of car-
diovascular complications and mortality.
The challenge to the physician is to select
the patient subgroups more likely to ben-
efit from screening(30). Current guidelines
recommend screening it in asymptomatic
diabetic patients selected for high cardio-
vascular risk (i.e., with two or more other
cardiovascular risk factors, or peripheral or
carotid arterial disease, or proteinuria).
ECG stress test can be recommended in
first intention if maximal heart rate can be
achieved. For patient with inconclusive
ECG stress test, myocardial scintigraphy
seems more accurate than stress echocar-
diography. Coronary angiogram should be
performed in case of positive stress test(31).
The second phase of the DIAD study (n
= 1123) already showed that screening with
MPS all asymptomatic diabetic patients is
not cost-effective(32). The cumulative car-
diac event rate was 2.9% over a follow-up
of 4.8 ± 0.9 years for an average of 0.6%
per year. The positive predictive value of
Table 5 Multiple logistic regression analysis for ischemia (p value < 0.05).
Age (< 60 / ≥ 60 years)
Neuropathy (Yes/No)
MPS
abnormal
n = 12
7/5
10/2
MPS
normal
n = 47
42/5
21/26
p value
0.039
0.045
OR
5.21
5.54
CI 95% OR
1.09–24.96
1.04–29.58
MPS, myocardial perfusion scintigraphy; OR, odds ratio; CI, confidence interval.
Table 6 Univariate logistic regression analysis for ischemia in DM2 patients (p value < 0.05).
Age (< 60 / ≥ 60 years)
Retinopathy (Yes/No)
Nephropathy (Yes/No)
– Microalbuminuria
– Macroalbuminuria
Neuropathy (Yes/No)
MPS
abnormal
n = 10
5/5
8/2
8/2
3/8
5/8
9/1
MPS
normal
n = 33
28/5
13/20
14/19
7/14
7/14
15/18
p value
0.031
0.036
NS
NS
0.043
0.032
OR
5.6
6.15
5.43
4.07
6.79
10.8
CI 95% OR
1.17–26.72
1.13–33.67
0.99–29.61
0.56–29.73
1.06–43.36
1.23–95.21
MPS, myocardial perfusion scintigraphy; OR, odds ratio; CI, confidence interval; NS, non significant.
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having moderate or large myocardial per-
fusion defects was only 12%. Thus routine
screening did not appear to affect overall
outcome(32). However, during the course of
study there was a significant and equivalent
increase in primary medical prevention in
both groups and that can be an important
bias. Nonprotocol stress tests were done
during follow-up when clinically indicated
in both groups and probably led to more
stringent measures to control the DM, thus
patients might have presented a better out-
come than initially expected. Therefore, the
goal is to identify the diabetic subgroups
with the highest risk for future cardiac
events to offer them more aggressive inten-
sive medical therapy or coronary revascula-
rization and optimum medical therapy(33).
In our series of DM1 and DM2 patients,
according to univariate logistic regression
analysis, these subgroups would be initially
determined by the patient’s age (60 years
and above), presence of peripheral neur-
opathy, nephropathy, retinopathy, or stress
ECG positive for ischemia. When the same
patients were evaluated by multiple logis-
tic regression analysis, the best predictors
to indicate an abnormal myocardial perfu-
sion scintigraphy would be age, or presence
of peripheral diabetic neuropathy.
When considering the univariate logis-
tic regression analysis of the subgroup of
DM2 patients, individuals with an in-
creased likelihood of myocardial perfusion
defects are those which have age 60 years
old and above, presence of retinopathy,
peripheral neuropathy, or macroalbuminuric
nephropathy. Attempting an even more
accurate statistical selection, the multiple
logistic regression analysis showed that the
main predictor of silent ischemia was the
presence of peripheral neuropathy, with a
10.8 times greater risk of silent ischemia in
an asymptomatic diabetic patient type 2.
Interestingly, if we consider that patients
with peripheral neuropathy may also
present autonomic neuropathy, as both are
part of the same complication, our results
are in agreement with the findings of the
first phase of the DIAD study(2), in which
the strongest predictor of silent ischemia
was reduced heart rate response to Valsalva
maneuver.
Currently there is an even greater con-
cern in reducing as much as possible the ex-
posure of patients to ionizing radiation. For
such, more modern equipment allow the
use of a dose of 5 mCi (185 MBq) of sesta-
mibi-99mTc at rest imaging and of 15 mCi
(555 MBq) in stress imaging for one-day
protocol. Another alternative is to use the
two-day protocol with fixed doses of 7 mCi
(259 MBq) in each step. Some authors also
suggest the possibility of performing first
the stress imaging after the injection of 7
mCi (259 MBq), and the rest imaging only
if the stress phase is abnormal(34,35). How-
ever, this proposal remains controversial.
Another important issue related to MPS is
the definition of which patients might ben-
efit from revascularization, considering
myocardial viability and contractile re-
serve(36,37).
Future prospective studies including
only those subgroups of diabetic patients
at high risk for CAD are needed to assess
the real benefit of offering these patients a
more aggressive therapy.
CONCLUSION
In our series, about one in five asymp-
tomatic diabetic patients had silent is-
chemia. Approximately 40% of DM1 and
DM2 asymptomatic patients with silent is-
chemia had a high risk of cardiac events,
with perfusion defects of 10% and higher.
The predictors of a myocardial scintig-
raphy showed perfusion abnormalities
were: age 60 years and above; stress ECG
positive for ischemia; presence of any vas-
cular complication of diabetes: retinopathy,
nephropathy, or peripheral neuropathy.
Peripheral neuropathy was the main predic-
tor for silent ischemia in asymptomatic
DM2 patients.
It is possible to clinically imply that
screening of a subgroup of diabetic patients
at high risk could lead to early detection
and treatment of CAD, which could be
useful in reducing morbidity and mortality
of these patients.
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